Dr. Mark Schiebler is Business Development Director at Roche. He is responsible for leading a range of licensing projects in Oncology and Research Technologies. He works closely with the research and development organizations to build partnerships for new transformative therapies and discovery platforms. He has more than 15 years of experience in pharma, biotechnology and drug discovery. Previously, he was Team Lead for Lead Generation at Syngenta. For his post-doctoral research, he was the Cambridge Rosetrees Fellow in Nanomedicine. He received his PhD in Immunology from the University of Cambridge and MA in Biology from the University of Oxford.

Helen is a public policy expert specializing in China’s social and health policies, with experience in China’s health-related market landscape. She has worked on projects related to the pharmaceutical, MedTech, and broader health industries in China. Prior to CMG, Helen has worked in a boutique consultancy in Beijing serving the industrial sector as well as interned with both the UN in New York and the ILO in Geneva.

Xiaohua Zhang has around 20 years of experience in Regulatory Affairs. She has worked in various sectors, including a local pharmaceutical company in China, a Contract Research Organization (CRO), and a global pharmaceutical company, where she held leadership roles in RA.

Currently, Xiaohua works at Tigermed as the RA Biological Team Leader, overseeing a team of 17 members. In her role, she is primarily responsible for global regulatory strategy and submissions. Xiaohua has extensive experience in managing regulatory affairs for antibodies, cell and gene therapeutic products, and vaccines, both in China and internationally (including regions like the US, EU, South Africa, and Latin America).

Her team is highly experienced in regulatory strategy and has worked closely with regulatory authorities such as the CDE, FDA, EMA, and others. This expertise allows them to support clients in accelerating approval processes in China and other regions worldwide.